Wolters Kluwer Launches Capego Practice Management - A Cloud Solution for Modern Tax and Accounting Firms
This cloud-based software system brings together everything tax and accounting firms need into one powerful, connected platform that’s fully integrated with the Capego suite of products
Wolters Kluwer Tax & Accounting Denmark is proud to announce the launch of Capego Practice Management, a cloud-native solution designed to empower tax and accounting firms with smarter, more connected workflows. The Capego suite now brings together everything firms need—from client data and task management to invoicing and compliance—into one secure, scalable system.
“Capego Practice Management represents a major leap forward in how tax and accounting firms can operate in today’s digital-first world,” said Stefan Wahle, Vice President & General Manager, Wolters Kluwer Tax & Accounting, Europe Region North. “By bringing together client collaboration, task management, compliance, and invoicing into one fully integrated platform, we’re helping firms work smarter, stay compliant, and deliver exceptional service—now and into the future.”
Capego Practice Management builds on the capabilities of our global cloud-based accounting software CCH iFirm to streamline workflows, enhance collaboration and increase the efficiency of operations.
Smarter practice management. Built for today – ready for tomorrow.
Capego Practice Management is built to support the modern, digital tax and accounting firm. It provides a comprehensive overview of assignments, deadlines, and resources, enabling firms to streamline operations, increase transparency, and collaborate more efficiently with clients.
Key Benefits:
- Cloud-Based Efficiency: Manage tasks, track time, invoice clients, and ensure compliance—all from a single, intuitive platform.
- Integrated Modules: Closing of Books, Tax, e-signing, and KYC work seamlessly together to support industry-standard workflows.
- Scalability & Security: Designed for firms of all sizes, with secure access and future-ready infrastructure.
- Centralized Client Database: A holistic view of clients, projects, and resources for smarter decision-making.
Capego Practice Management is designed to meet the evolving needs of today’s tax and accounting firms. For new clients, it offers a modern, cloud-based platform that brings together everything needed to deliver high-quality services. For existing customers migrating from on-premise systems, it delivers the familiarity of current tools with the added benefits of scalability, flexibility, and seamless integration.
Capego is a cloud-based software suite of products, designed to support accounting, auditing, and tax professionals. Capego streamlines financial workflows, enhances collaboration, and helps ensure compliance with local regulations.
To learn more about Capego Practice Management, please visit: https://www.wolterskluwer.com/en/solutions/capego-dk/capego-practice-management-dk
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com and follow us on LinkedIn, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250831606233/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer lancerer Capego Practice Management – en cloud-løsning til moderne revisions- og bogføringsfirmaer1.9.2025 01:00:00 CEST | Pressemeddelelse
Dette cloudbaserede softwaresystem samler alt, hvad revisions- og bogføringsfirmaer har brug for, i én kraftfuld, forbundet platform, der er fuldt integreret med Capego-produktserien Wolters Kluwer Tax & Accounting Danmark er stolte af at kunne annoncere lanceringen af Capego Practice Management, en cloud-baseret løsning designet til at give revisions- og bogføringsfirmaer smartere og mere integrerede arbejdsgange. Capego-pakken samler nu alt, hvad firmaer har brug for – fra kundedata og opgavestyring til fakturering og compliance – i ét sikkert, skalerbart system. "Capego Practice Management repræsenterer et stort fremskridt i måden, hvorpå revisions- og bogføringsfirmaer kan operere i dagens digitale verden," siger Stefan Wahle, vicepræsident og general manager, Wolters Kluwer Tax & Accounting, Europa Region Nord. "Ved at samle kundesamarbejde, opgavestyring, compliance og fakturering i én fuldt integreret platform hjælper vi firmaer med at arbejde smartere, overholde reglerne og lev
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom